New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, SSNLF, BIIBMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Check below for free stories on MRK;SSNLF;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2014
10:25 EDTBIIBBiogen price target raised to $420 from $370 at Piper Jaffray
Subscribe for More Information
09:50 EDTBIIBBiogen says strategic bias still tuck-in acquisitions
Subscribe for More Information
09:37 EDTBIIBBiogen says 'clearly' has considered tax inversion
Subscribe for More Information
09:25 EDTBIIBBiogen sees Japan as an attractive growth opportunity for company
Says remains committed to SG&A leverage in 2014. Says guidance assumes Tecfidera EU uptake similar to U.S.
09:17 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBIIBBiogen says received letter from EU saying PLEGRIDY has been approved
Subscribe for More Information
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
06:50 EDTBIIBBiogen raises FY14 EPS to $12.90-$13.10 from $11.35-$11.45, consensus $11.53
Subscribe for More Information
06:48 EDTBIIBBiogen reports Q2 Tecfidera revenue $700M; Reports Q2 Avonex revenue $774M
Subscribe for More Information
06:47 EDTBIIBBiogen reports Q2 adjusted EPS $3.49, consensus $2.83
Reports Q2 revenue $2.42B, consensus $2.16B; Non-GAAP diluted EPS was benefited by approximately 15c, following the approval from an agreement with the Italian National Medicines Agency relating to Tysabri sales in Italy.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
06:21 EDTSSNLFWitsView: Acer surpasses Samsung in Chromebook shipments in Q2, DigiTimes says
Subscribe for More Information
06:17 EDTSSNLFGlobal notebook shipments to increase 4.3% in Q3, DigiTimes Research says
Subscribe for More Information
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
07:20 EDTSSNLFSamsung China supplier stops production amid investigation, Reuters says
Subscribe for More Information
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 18, 2014
06:08 EDTSSNLFSamsung mobile executives return part of bonuses, Yonhap News reports
Subscribe for More Information
06:02 EDTSSNLFDRAMeXchange: Global DRAM module sales grew 32% in 2013, DigiTimes says
Subscribe for More Information
July 17, 2014
06:43 EDTSSNLFTSMC expects to lose out to competitors in 14/16nm segment, DigiTimes says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use